Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
GHRS
GHRS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GHRS News
Helus Pharma Advances New Drug for Anxiety Treatment
1d ago
Newsfilter
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
1d ago
PRnewswire
GH Research Reports FY 2025 Financial Results
4d ago
seekingalpha
Helus Pharma Advances Mental Health Drug Development
Feb 27 2026
Newsfilter
Helus Pharma Advances Psychedelic Drug Clinical Trials
Feb 27 2026
PRnewswire
US Stocks Close Higher, S&P 500 Hits One-Week High
Jan 06 2026
NASDAQ.COM
US Stock Indices Rise with Energy Stocks Leading Gains
Jan 05 2026
NASDAQ.COM
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
Jan 05 2026
Benzinga
US Stocks Rise as Energy Shares Surge on Venezuela Situation
Jan 05 2026
NASDAQ.COM
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
Jan 05 2026
Benzinga
GH Research (GHRS) FDA Lifts Clinical Hold on GH001, Shares Surge 42%
Jan 05 2026
NASDAQ.COM
GH Research Secures FDA Clearance for GH001 Clinical Trial
Jan 05 2026
Benzinga
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
Jan 05 2026
Benzinga
Bank OZK Raises Quarterly Dividend to 46 Cents Per Share
Jan 05 2026
Benzinga
GH Research PLC Receives FDA Clearance for GH001 Clinical Investigation, Targeting Phase 3 Launch in 2026
Jan 05 2026
Globenewswire
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
Jan 05 2026
Benzinga
Show More News
